摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

sodium 1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate | 1393924-33-8

中文名称
——
中文别名
——
英文名称
sodium 1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate
英文别名
sodium;(1R)-1-[[(2R,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate
sodium 1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate化学式
CAS
1393924-33-8
化学式
C30H39N2O4S2*Na
mdl
——
分子量
578.772
InChiKey
BFSUQRXCGZLFGC-CHHHCJMRSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.49
  • 重原子数:
    39
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    76.5
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    5-溴戊酸甲酯sodium 1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate乙腈 为溶剂, 反应 24.0h, 以86.2%的产率得到5-[1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl-methyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbothioylsulfanyl]-pentanoic acid methyl ester
    参考文献:
    名称:
    盐酸艾美汀的二硫代氨基甲酸酯衍生物在前列腺癌细胞系中的设计,合成及细胞毒性研究
    摘要:
    通过使依替丁的N2'-位衍生化,合成了一个少量的依替丁二硫代氨基甲酸酯衍生物库,产率为25-86%。这些化合物在雄激素受体阳性LNCaP和雄激素受体阴性PC3和DU145前列腺癌细胞系中的抗癌评估显示出时间依赖性和剂量依赖性细胞毒性。除化合物4c外,本研究中的所有二硫代氨基甲酸酯类似物在所有前列腺癌细胞系中均显示出显着的效力(无论是雄激素受体阳性还是阴性),其细胞毒性IC 50值范围为1.312±0.032μM。治疗第7天时为5.201±0.125μM。与二硫代氨基甲酸钠盐1相比,所有二硫代氨基甲酸酯类似物(2和4a – 4g  )在治疗的第7天显示出比化合物1(PC3,IC 50  = 0.087±0.005μM; DU145,IC 50  = 0.079±0.003μM和LNCaP,IC 50 = 0.079± 0.003μM)低的细胞毒性。因此,似乎化合物1的S-烷基化导致更稳定的二
    DOI:
    10.1016/j.bmc.2015.06.072
  • 作为产物:
    描述:
    二硫化碳盐酸吐根碱 在 sodium hydroxide 作用下, 以 乙醇 为溶剂, 反应 2.25h, 以82%的产率得到sodium 1-(3-ethyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylmethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbodithioate
    参考文献:
    名称:
    盐酸艾美汀的二硫代氨基甲酸酯衍生物在前列腺癌细胞系中的设计,合成及细胞毒性研究
    摘要:
    通过使依替丁的N2'-位衍生化,合成了一个少量的依替丁二硫代氨基甲酸酯衍生物库,产率为25-86%。这些化合物在雄激素受体阳性LNCaP和雄激素受体阴性PC3和DU145前列腺癌细胞系中的抗癌评估显示出时间依赖性和剂量依赖性细胞毒性。除化合物4c外,本研究中的所有二硫代氨基甲酸酯类似物在所有前列腺癌细胞系中均显示出显着的效力(无论是雄激素受体阳性还是阴性),其细胞毒性IC 50值范围为1.312±0.032μM。治疗第7天时为5.201±0.125μM。与二硫代氨基甲酸钠盐1相比,所有二硫代氨基甲酸酯类似物(2和4a – 4g  )在治疗的第7天显示出比化合物1(PC3,IC 50  = 0.087±0.005μM; DU145,IC 50  = 0.079±0.003μM和LNCaP,IC 50 = 0.079± 0.003μM)低的细胞毒性。因此,似乎化合物1的S-烷基化导致更稳定的二
    DOI:
    10.1016/j.bmc.2015.06.072
点击查看最新优质反应信息

文献信息

  • [EN] EMETINE DERIVATIVES, PRODRUGS CONTAINING SAME, AND METHODS OF TREATING CONDITIONS USING SAME<br/>[FR] DÉRIVÉS D'ÉMÉTINE, PRODROGUES CONTENANT CES DÉRIVÉS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES AU MOYEN DE CES PRODROGUES
    申请人:UNIV HOWARD
    公开号:WO2012162175A1
    公开(公告)日:2012-11-29
    Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2'-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.
    本文提供了一些化合物,它们是伊美啶衍生物,可以用作前药,在特定细胞条件下选择性地发生活化以释放伊美啶。在一个方面,通过将阻断基固定到伊美啶分子上,通过在癌症/肿瘤微环境中选择性水解的方式,可以将其衍生化到N2'-位置。这种化合物比伊美啶更少细胞毒性,并在非癌细胞中基本无活性。在一个方面,本文描述的化合物可用于治疗转移性和非转移性癌症,包括乳腺癌、前列腺癌、肺癌和白血病等。
  • Design, Synthesis, and Evaluation of pH-Dependent Hydrolyzable Emetine Analogues as Treatment for Prostate Cancer
    作者:Emmanuel S. Akinboye、Marc D. Rosen、Samuel R. Denmeade、Bernard Kwabi-Addo、Oladapo Bakare
    DOI:10.1021/jm300426q
    日期:2012.9.13
    The N-2' position of the natural product emetine has been derivatized to thiourea, urea, sulfonamide, dithiocarbamate, carbamate, and pH responsive hydrolyzable amide analogues. In vitro studies of these analogues in PC3 and LNCaP prostate cancer cell lines showed that the analogues are generally less cytotoxic (average IC50 ranging from 0.079 to 10 mu M) than emetine (IC50 ranging from 0.0237 to 0.0329 mu M). The pH sensitive sodium dithiocarbamate salt 13 and the amide analogues 21, 22, 26 (obtained from maleic and citraconic anhydrides) showed the most promise as acid-activatable prodrugs under mildly acidic conditions found in the cancer microenvironment. These prodrugs released 12-83% of emetine at pH 6.5 and 41-95% emetine at pH 5.5. Compounds 13 and 26 were further shown to exhibit increased cytotoxicity in PC3 cell culture medium that was already below pH 7.0 at the time of treatment.
  • Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines
    作者:Emmanuel S. Akinboye、Zebalda D. Bamji、Bernard Kwabi-Addo、David Ejeh、Robert L. Copeland、Samuel R. Denmeade、Oladapo Bakare
    DOI:10.1016/j.bmc.2015.06.072
    日期:2015.9
    salt 1, all the dithiocarbamate ester analogs (2 and 4a–4g) displayed lower cytotoxicity than compound 1 (PC3, IC50 = 0.087 ± 0.005 μM; DU145, IC50 = 0.079 ± 0.003 μM and LNCaP, IC50 = 0.079 ± 0.003 μM) on day 7 of treatment. Consequently, it appears that S-alkylation of compound 1 leads to a more stable dithiocarbamate ester derivative that resulted in lower anticancer activity in the prostate cancer
    通过使依替丁的N2'-位衍生化,合成了一个少量的依替丁二硫代氨基甲酸酯衍生物库,产率为25-86%。这些化合物在雄激素受体阳性LNCaP和雄激素受体阴性PC3和DU145前列腺癌细胞系中的抗癌评估显示出时间依赖性和剂量依赖性细胞毒性。除化合物4c外,本研究中的所有二硫代氨基甲酸酯类似物在所有前列腺癌细胞系中均显示出显着的效力(无论是雄激素受体阳性还是阴性),其细胞毒性IC 50值范围为1.312±0.032μM。治疗第7天时为5.201±0.125μM。与二硫代氨基甲酸钠盐1相比,所有二硫代氨基甲酸酯类似物(2和4a – 4g  )在治疗的第7天显示出比化合物1(PC3,IC 50  = 0.087±0.005μM; DU145,IC 50  = 0.079±0.003μM和LNCaP,IC 50 = 0.079± 0.003μM)低的细胞毒性。因此,似乎化合物1的S-烷基化导致更稳定的二
查看更多

同类化合物

盐酸吐根酚碱 盐酸吐根碱 吐根碱氢溴酸盐 吐根碱氢溴酸盐 吐根碱 依米丁二盐酸盐水合物 依米丁 二盐酸吐根碱 九节碱 7',10,11-三甲氧基-1',2'-二去氢依米丁-6'-醇草酸盐(1:1) 2-[(6,7-二甲氧基-1,2,3,4-四氢异喹啉-1-基)甲基]-3-乙基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉四水合物二盐酸盐 1',2'-二去氢-7',10,11-三甲氧基依米丁-6',9-二醇 (+)-吐根素二盐酸盐水合物 (1RS,2S,3R,11bR)-2-benzoyl-1-(3-ethyl-9,10-dimethoxy-4-oxo-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-ylmethyl)-6-7-dimethoxy-1,2-dihydroisoquinoline-1-carbonitrile (2SR,3RS,11bSR)-2-benzoyl-1-(3-ethyl-9,10-dimethoxy-4-oxo-1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizin-2-ylmethyl)-6,7-dimethoxy-1,2-dihydroisoquinoline-1-carbonitrile 2'-N-(1''-deoxy-1''-β-D-fructopyranosyl)cephaeline 7'-O-demethylcephaeline 7′,10-dide-O-methylcephaeline 2′-(N-carboxy-β-alanyl)-tert-butyl emetine ester 7'-O-demethylisocephaeline N-Methyl-emetin Emetine (or isoemetine), dihydrochloride Emetine hydrobromide 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(o-anisyloxy)-2-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride 2H-Benzo(a)quinolizine, 3-ethyl-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6-isopentoxy-7-methoxy-1-isoquinolyl)methyl)-, phosphate (2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine;triiodobismuthane 2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine;hydron;dichloride 11b-epi-emetine 11b-epi-isoemetine (2S,3R,11bS)-2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine;hydron;dibromide 1-[(1R)-1-[[(2R,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-3-tert-butylsulfanylpropan-2-ol;hydron;dichloride Emetine, 2'-(3-(6-chloro-o-toluidino)-2-hydroxypropyl)-, trihydrochloride Emetine, 2'-(2-hydroxy-3-(4-methyl-1-piperazinyl)propyl)-, tetrahydrochloride 1-[(1R)-1-[[(2R,3R,11bS)-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl]methyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-3-(furan-2-ylmethylsulfanyl)propan-2-ol;hydron;dichloride 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(2-ethylhexyloxy)-2-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(2-hydroxy-3-(1-methylpropylthio)propyl)-1-isoquinolyl)methyl)-, dihydrochloride, trihydrate 2H-Benzo(a)quinolizine, 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-(3-(3,4-dimethoxycarbaniloylmethylthio)-2-hydroxypropyl)-1-isoquinolyl)methyl)-, dihydrochloride <2S-<2α(S*),3β,11β>>-9-benzyloxy-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-1-isoquinolyl)methyl-3-ethyl-1,3,4,6,7,11b-hexahydro-10-methoxy-2H-benzoquinolizine <2S-<2α(S*),3β,11β>>-3-ethyl-1,3,4,6,7,11b-hexahydro-9-hydroxy-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-1-isoquinolyl)methyl-10-methoxy-2H-benzoquinolizine <2S-<2α(R*),3β,11β>>-9-benzyloxy-2-(6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-1-isoquinolyl)methyl-3-ethyl-1,3,4,6,7,11b-hexahydro-10-methoxy-2H-benzoquinolizine Emetine, N-(1-carboxyprolyl)-, benzyl ester Emetine, 2'-(N-carboxyglycyl)-, tert-butyl ester Emetine dihydrobromide tetrahydrate 16,17-Dinoremetan, 1-ethyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-beta)-(+-)- 16,17-Dinoremetan, 1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha,2-alpha)-(+-)- 16,17-Dinoremetan, 1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-beta)-(+-)- 16,17-Dinoremetan, 1',2'-didehydro-1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha)-(+-)- 16,17-Dinoremetan, 1',2'-didehydro-1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-beta)-(+-)- 16,17-Dinoremetan, 1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha)-(+-)- 16,17-Dinoremetan, 1',2'-didehydro-1-methyl-6',7',10,11-tetramethoxy-, dihydrochloride, (1-alpha,2-alpha)-(+-)-